FDA Class II Recall: Glenmark's Atomoxetine Capsules Tainted by Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall of 133,824 bottles of Atomoxetine Capsules, USP, 25 mg, due to N-Nitroso Atomoxetine Impurity exceeding FDA limits. This voluntary recall, impacting U.S. nationwide distribution, signals critical CGMP deviations at the manufacturing facility, Glenmark Pharmaceuticals Ltd., Goa, India, posing significant supply chain and regulatory risks for procurement and regulatory affairs teams.
FDA Class II Recall: Glenmark's Atomoxetine Capsules Tainted by Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, has initiated a voluntary Class II recall (D-0240-2025) for 133,824 bottles of Atomoxetine Capsules, USP, 25 mg. This critical action, reported on February 26, 2025, and classified by the FDA on February 20, 2025, directly impacts the availability of this attention-deficit/hyperactivity disorder (ADHD) medication across the United States. The core issue, identified as a Current Good Manufacturing Practice (CGMP) deviation, involves the presence of N-Nitroso Atomoxetine Impurity at levels exceeding the FDA's recommended limits. N-Nitroso compounds are a class of substances of concern due to their potential genotoxic and carcinogenic properties, making strict adherence to impurity limits paramount for patient safety. For procurement directors, this event necessitates an immediate review of Atomoxetine 25 mg inventory and supply contracts to understand exposure to the affected lots, which include 19232506, 19232397, 19232415 (Exp.: 5/2025); 19233791 (Exp.: 8/2025); 19234248 (Exp.: 9/2025); 19240909 (Exp.: 2/2026); 19242598 (Exp.: 6/2026); 19243163, 19243122 (Exp.: 7/2026); and 19243884 (Exp.: 9/2026). The recall of NDC 16714-757-01 underscores the ongoing industry challenge with nitrosamine impurities in active pharmaceutical ingredients (APIs) and finished drug products.
Commercial Repercussions: U.S. Market Disruption for Atomoxetine 25 mg Supply
The recall of 133,824 bottles of Atomoxetine Capsules, USP, 25 mg, distributed nationwide within the U.S., represents a significant commercial disruption for the generic ADHD medication market. Glenmark Pharmaceuticals Inc., USA, as the recalling firm, bears the immediate responsibility for managing this Class II recall, which was initiated voluntarily by the company on January 29, 2025. The product, manufactured by Glenmark Pharmaceuticals Ltd. in Goa, India, was marketed for Northstar Rx LLC, Memphis, TN. This situation directly impacts Northstar Rx LLC's ability to supply Atomoxetine 25 mg, potentially leading to supply chain gaps for pharmacies and healthcare providers. Supply chain VPs must assess the immediate impact on their distribution networks, identify affected stock, and manage returns efficiently. The substantial quantity of recalled units suggests that downstream formulators or distributors relying on this specific Glenmark-sourced product will face immediate pressure to secure alternative supplies to prevent shortages. Business development executives should evaluate the competitive landscape for Atomoxetine, as this recall may create opportunities for other generic manufacturers to capture market share, particularly for the 25 mg dosage form. This event highlights the critical importance of robust supplier qualification and ongoing quality monitoring, especially for products sourced from international manufacturing facilities.
Regulatory Scrutiny: CGMP Deviations and Future Compliance for Glenmark Pharma
The underlying cause of this Atomoxetine recall—CGMP deviations leading to elevated N-Nitroso Atomoxetine Impurity—places Glenmark Pharmaceuticals Ltd.'s manufacturing operations in Goa, India, under heightened regulatory scrutiny. While this is a firm-initiated voluntary recall, its Class II classification indicates that the impurity could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. Regulatory affairs heads must recognize that an ongoing recall of this magnitude often precedes or accompanies more stringent FDA oversight. The FDA will expect Glenmark Pharmaceuticals Ltd. to conduct a thorough investigation into the root causes of the CGMP deviations and implement comprehensive corrective and preventive actions (CAPA). Failure to adequately address these manufacturing quality issues could escalate to further regulatory actions, including potential Warning Letters, increased import surveillance, or even Import Alerts for products originating from the Goa facility. This event serves as a critical reminder for all chemical and life sciences companies that robust quality management systems and strict adherence to CGMP are non-negotiable, particularly for products distributed in highly regulated markets like the U.S. Proactive engagement with regulatory bodies and transparent communication regarding remediation efforts will be crucial for Glenmark to restore confidence and ensure continued market access for its products.